Xenon Pharmaceuticals Inc.
XENE
$40.15
$1.092.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 42.00% | 31.99% | 25.60% | 19.06% | 20.36% |
| Gross Profit | -37.78% | -27.63% | -25.60% | -19.06% | -20.46% |
| SG&A Expenses | 22.44% | 41.22% | 48.05% | 49.72% | 55.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.09% | 34.12% | 30.48% | 25.44% | 27.52% |
| Operating Income | -33.93% | -30.78% | -30.48% | -25.44% | -27.61% |
| Income Before Tax | -41.76% | -35.36% | -30.51% | -22.90% | -22.21% |
| Income Tax Expenses | -1,443.11% | -2,296.47% | -1,300.34% | -142.40% | -145.50% |
| Earnings from Continuing Operations | -39.77% | -33.32% | -28.48% | -21.90% | -21.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.77% | -33.32% | -28.48% | -21.90% | -21.58% |
| EBIT | -33.93% | -30.78% | -30.48% | -25.44% | -27.61% |
| EBITDA | -35.01% | -31.83% | -31.47% | -26.08% | -26.81% |
| EPS Basic | -29.45% | -18.59% | -10.19% | -5.63% | -9.83% |
| Normalized Basic EPS | -30.82% | -19.25% | -9.77% | -3.35% | -7.73% |
| EPS Diluted | -29.45% | -18.59% | -10.19% | -5.63% | -9.83% |
| Normalized Diluted EPS | -30.82% | -19.25% | -9.77% | -3.35% | -7.73% |
| Average Basic Shares Outstanding | 7.80% | 11.90% | 16.45% | 15.16% | 10.86% |
| Average Diluted Shares Outstanding | 7.80% | 11.90% | 16.45% | 15.16% | 10.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |